IN8BIO, INC.: management transactions · United States · SEC (Form 4)

About IN8BIO, INC.

IN8bio, Inc. (ticker: INAB) is a clinical-stage biopharmaceutical company listed on the Nasdaq market in the United States. For French-speaking investors, this is an innovative but highly speculative healthcare name focused on cellular immuno-oncology. The company develops gamma-delta (γδ) T-cell therapies, a subset of immune cells that it believes may offer a differentiated way to fight cancer while addressing some of the limitations of conventional approaches. IN8bio was founded in 2016 with the mission of developing next-generation therapies for cancer, and its scientific roots are tied to co-founder Lawrence Lamb’s work in gamma-delta T-cell biology. The company is headquartered in New York, New York, with primary scientific operations in Birmingham, Alabama, reflecting a common U.S. biotech setup in which corporate, capital-markets and R&D functions are split across locations. The core of IN8bio’s investment case is its proprietary DeltEx™ platform, which underpins a diversified set of product concepts, including autologous, allogeneic, iPSC-derived and genetically modified γδ T-cell therapies. The platform is designed to support both solid tumors and hematologic cancers, with a particular emphasis on high-unmet-need indications such as glioblastoma and certain leukemia settings. More recently, management has also highlighted a next-generation gamma-delta T-cell engager program, expanding the platform’s scope beyond oncology and into selected autoimmune disease applications. In other words, IN8bio is still primarily a clinical and scientific story: unlike commercial-stage biopharma companies, its valuation is driven far more by clinical data, manufacturing reproducibility, intellectual property and financing capacity than by current sales. From a competitive standpoint, IN8bio operates in a crowded and fast-moving cell-therapy landscape where several companies are trying to prove superior efficacy, safety and scalability. Its differentiation lies in the γδ biology angle, which the company positions as potentially offering advantages such as lower cytokine-release risk compared with some traditional T-cell engager or CAR-T approaches. Recent corporate developments have been important. In 2025 and 2026, management discussed progress across its INB-100, INB-200/400 and INB-600 programs, along with a private placement announced in December 2025 to help fund development of the INB-619 T-cell engager. In March 2025, the company also highlighted durable responses seen in its clinical programs. For investors, the key watchpoints remain clinical readouts, cash runway, dilution risk and the company’s ability to translate a promising scientific platform into reproducible, registrable clinical outcomes.